{"id":2741,"date":"2018-10-21T13:42:58","date_gmt":"2018-10-21T13:42:58","guid":{"rendered":"https:\/\/negargetni.com\/?p=2741"},"modified":"2024-09-04T08:52:10","modified_gmt":"2024-09-04T08:52:10","slug":"integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018","status":"publish","type":"post","link":"https:\/\/integragen.com\/en\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/","title":{"rendered":"INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018"},"content":{"rendered":"<p><em>Analysis of samples from the PETACC 8 phase III clinical trial shows that the level of miR-31 expression identifies sub-populations of stage III colon cancer patients who have benefited from the addition of cetuximab to FOLFOX adjuvant chemotherapy.<\/em><\/p>\n\n\n\n<p>IntegraGen today announced the presentation of results on miR-31 microRNA at the annual conference of the European Society for Medical Oncology (ESMO) in Munich. The study, entitled \"<em>miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: a retrospective analysis of the PETACC-8 trial,\" (<strong><a href=\"https:\/\/drive.google.com\/open?id=1WT4F2fPib_27hY3jQX8Cgluu0FI_103v\" target=\"_blank\" rel=\"noreferrer noopener\">link<\/a><\/strong>) is based on the analysis of tumor samples collected from more than 1n400 patients included in the prospective clinical trial&nbsp;<\/em><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03362684\" target=\"_blank\" rel=\"noreferrer noopener\">PETACC-8<\/a>&nbsp;Phase III<em>.<\/em><\/p>\n\n\n\n<p><em>The main results relate in particular to :<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>The fact that miR-31-3p and miR-31-5p expression are prognostic of progression-free survival (PFS) and overall survival (OS) in several subpopulations of phase III colon cancer patients.<\/em><\/li>\n\n\n\n<li><em>That the expression level of miR-31-3p and miR-31-5p identifies patients who have benefited from the addition of cetuximab to FOLFOX adjuvant chemotherapy.<\/em><\/li>\n\n\n\n<li><em>And that the level of expression of miR-31-5p specifically is predictive of cetuximab efficacy in three distinct subpopulations among the patients included in the study.<\/em><\/li>\n<\/ul>\n\n\n\n<p><em>&nbsp;<\/em>\"These results provide further evidence of the marker's ability to predict response to cetuximab therapy in colorectal cancer patients\" S\u00e9verine Martin-Lanner\u00e9e, PhD, R&amp;D project leader at IntegraGen and co-author of the study. \"While all our previous studies focused on patients with metastatic colon cancer, this new study demonstrates that a low level of expression of the marker allows us to identify patients in earlier, non-metastatic phases who have benefited from the addition of cetuximab to adjuvant chemotherapy, which could potentially broaden the biomarker's clinical applications.\"<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter\"><a href=\"https:\/\/drive.google.com\/open?id=1WT4F2fPib_27hY3jQX8Cgluu0FI_103v\" target=\"_blank\" rel=\"noreferrer noopener\"><img decoding=\"async\" src=\"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg\" alt=\"\" class=\"wp-image-1772\"\/><\/a><\/figure>","protected":false},"excerpt":{"rendered":"<p>Analysis of samples from the PETACC 8 phase III clinical trial demonstrates that miR-31 expression levels identify sub-populations of stage III colon cancer patients who have benefited from the addition of cetuximab to FOLFOX adjuvant chemotherapy. IntegraGen today announced the presentation of results on the microRNA...<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ca_portfolio_gallery_project_year":"","ca_portfolio_gallery_client":"","ca_portfolio_gallery_skills":"","ca_portfolio_gallery_url":"","ca_portfolio_gallery_images":"","_eb_attr":"","footnotes":""},"categories":[5,1],"tags":[],"class_list":["post-2741","post","type-post","status-publish","format-standard","hentry","category-actualite","category-toutes-les-categories"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&#039;UNE \u00c9TUDE \u00c9LARGISSANT L&#039;IMPACT DE LA MESURE DE L&#039;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&#039;ESMO 2018<\/title>\n<meta name=\"description\" content=\"L\u2019analyse des \u00e9chantillons issus de l\u2019essai clinique de phase III PETACC 8 d\u00e9montre que le niveau d\u2019expression du miR-31 permet d\u2019identifier des\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/integragen.com\/en\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&#039;UNE \u00c9TUDE \u00c9LARGISSANT L&#039;IMPACT DE LA MESURE DE L&#039;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&#039;ESMO 2018\" \/>\n<meta property=\"og:description\" content=\"L\u2019analyse des \u00e9chantillons issus de l\u2019essai clinique de phase III PETACC 8 d\u00e9montre que le niveau d\u2019expression du miR-31 permet d\u2019identifier des\" \/>\n<meta property=\"og:url\" content=\"https:\/\/integragen.com\/en\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"IntegraGen\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-21T13:42:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-04T08:52:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg\" \/>\n<meta name=\"author\" content=\"marine Deruy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marine Deruy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/\"},\"author\":{\"name\":\"marine Deruy\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/person\\\/f7984826e661ce0b8d186cd690160607\"},\"headline\":\"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&rsquo;UNE \u00c9TUDE \u00c9LARGISSANT L&rsquo;IMPACT DE LA MESURE DE L&rsquo;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&rsquo;ESMO 2018\",\"datePublished\":\"2018-10-21T13:42:58+00:00\",\"dateModified\":\"2024-09-04T08:52:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/\"},\"wordCount\":406,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/mir-31petacc-8.jpg\",\"articleSection\":[\"Actualit\u00e9s\",\"Toutes les Cat\u00e9gories\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/\",\"name\":\"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D'UNE \u00c9TUDE \u00c9LARGISSANT L'IMPACT DE LA MESURE DE L'EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L'ESMO 2018\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/mir-31petacc-8.jpg\",\"datePublished\":\"2018-10-21T13:42:58+00:00\",\"dateModified\":\"2024-09-04T08:52:10+00:00\",\"description\":\"L\u2019analyse des \u00e9chantillons issus de l\u2019essai clinique de phase III PETACC 8 d\u00e9montre que le niveau d\u2019expression du miR-31 permet d\u2019identifier des\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#primaryimage\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/mir-31petacc-8.jpg\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/mir-31petacc-8.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/integragen.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\\\/\\\/integragen.com\\\/actualite\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&rsquo;UNE \u00c9TUDE \u00c9LARGISSANT L&rsquo;IMPACT DE LA MESURE DE L&rsquo;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&rsquo;ESMO 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"name\":\"IntegraGen - Clinical Genomic Experts\",\"description\":\"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CRO\",\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"alternateName\":\"IntegraGen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/integragen.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\",\"name\":\"IntegraGen\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"width\":2478,\"height\":684,\"caption\":\"IntegraGen\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/integragen\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/person\\\/f7984826e661ce0b8d186cd690160607\",\"name\":\"marine Deruy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"caption\":\"marine Deruy\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018","description":"Analysis of samples from the PETACC 8 phase III clinical trial shows that the level of miR-31 expression identifies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/integragen.com\/en\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/","og_locale":"en_US","og_type":"article","og_title":"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D'UNE \u00c9TUDE \u00c9LARGISSANT L'IMPACT DE LA MESURE DE L'EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L'ESMO 2018","og_description":"L\u2019analyse des \u00e9chantillons issus de l\u2019essai clinique de phase III PETACC 8 d\u00e9montre que le niveau d\u2019expression du miR-31 permet d\u2019identifier des","og_url":"https:\/\/integragen.com\/en\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/","og_site_name":"IntegraGen","article_published_time":"2018-10-21T13:42:58+00:00","article_modified_time":"2024-09-04T08:52:10+00:00","og_image":[{"url":"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg","type":"","width":"","height":""}],"author":"marine Deruy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"marine Deruy","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#article","isPartOf":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/"},"author":{"name":"marine Deruy","@id":"https:\/\/integragen.com\/#\/schema\/person\/f7984826e661ce0b8d186cd690160607"},"headline":"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&rsquo;UNE \u00c9TUDE \u00c9LARGISSANT L&rsquo;IMPACT DE LA MESURE DE L&rsquo;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&rsquo;ESMO 2018","datePublished":"2018-10-21T13:42:58+00:00","dateModified":"2024-09-04T08:52:10+00:00","mainEntityOfPage":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/"},"wordCount":406,"commentCount":0,"publisher":{"@id":"https:\/\/integragen.com\/#organization"},"image":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg","articleSection":["Actualit\u00e9s","Toutes les Cat\u00e9gories"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/","url":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/","name":"INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018","isPartOf":{"@id":"https:\/\/integragen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#primaryimage"},"image":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg","datePublished":"2018-10-21T13:42:58+00:00","dateModified":"2024-09-04T08:52:10+00:00","description":"Analysis of samples from the PETACC 8 phase III clinical trial shows that the level of miR-31 expression identifies","breadcrumb":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#primaryimage","url":"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/mir-31petacc-8.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/integragen.com\/toutes-les-categories\/integragen-presente-les-resultats-dune-etude-elargissant-limpact-de-la-mesure-de-lexpression-du-mir-31-aux-patients-atteints-de-cancer-du-colon-de-stade-iii-lors-de-lesmo-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/integragen.com\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/integragen.com\/actualite\/"},{"@type":"ListItem","position":3,"name":"INTEGRAGEN PR\u00c9SENTE LES R\u00c9SULTATS D&rsquo;UNE \u00c9TUDE \u00c9LARGISSANT L&rsquo;IMPACT DE LA MESURE DE L&rsquo;EXPRESSION DU MIR-31 AUX PATIENTS ATTEINTS DE CANCER DU C\u00d4LON DE STADE III LORS DE L&rsquo;ESMO 2018"}]},{"@type":"WebSite","@id":"https:\/\/integragen.com\/#website","url":"https:\/\/integragen.com\/","name":"IntegraGen - Clinical Genomic Experts","description":"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CROs","publisher":{"@id":"https:\/\/integragen.com\/#organization"},"alternateName":"IntegraGen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/integragen.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/integragen.com\/#organization","name":"IntegraGen","url":"https:\/\/integragen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/","url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","width":2478,"height":684,"caption":"IntegraGen"},"image":{"@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/integragen\/"]},{"@type":"Person","@id":"https:\/\/integragen.com\/#\/schema\/person\/f7984826e661ce0b8d186cd690160607","name":"marine Deruy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","caption":"marine Deruy"}}]}},"_links":{"self":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/2741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/comments?post=2741"}],"version-history":[{"count":1,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/2741\/revisions"}],"predecessor-version":[{"id":2742,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/2741\/revisions\/2742"}],"wp:attachment":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/media?parent=2741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/categories?post=2741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/tags?post=2741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}